Table 3.

Univariable and Multivariable Analysis for Clinical Failure at 96 Weeks (ART96)

Marker >Q3 (ART24)	Overall	Case	Control	Univariable Analysis		Multivariable Analysis Model 1a		Multivariable Analysis Model 2b
				IRR (95% CI)	P Value	IRR (95% CI)	P Value	IRR (95% CI)	P Value
IL-6	34 of 249 (14%)	6 of 57 (11%)	28 of 192 (15%)	0.65 (.28–1.52)	.33	0.62 (.25–1.52)	.29	0.62 (.25–1.54)	.30
IP-10	5 of 249 (2%)	2 of 57 (4%)	3 of 192 (2%)	2.39 (.58–9.79)	.23	2.27 (.45–11.33)	.32	2.35 (.48–11.78)	.30
IL-18	16 of 242 (7%)	8 of 56 (14%)	8 of 186 (4%)	2.86 (1.35–6.04)	.006	3.03 (1.27–7.20)	.012	2.99 (1.22–7.31)	.02
sCD14	33 of 246 (13%)	13 of 54 (24%)	20 of 192 (10%)	2.42 (1.30–4.51)	.006	2.17 (1.02–4.62)	.045	2.08 (.96–4.49)	.06
TNF-α	9 of 249 (4%)	3 of 57 (5%)	6 of 192 (3%)	1.23 (.38–3.93)	.73	1.05 (.29–3.73)	.94	0.99 (.28–3.59)	>.95
IFN-γ	36 of 249 (14%)	1 of 57 (2%)	35 of 192 (18%)	0.10 (.01–.74)	.02	0.08 (.01–.61)	.02	0.08 (.01–.62)	.02

Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; HIV, human immunodeficiency virus; IFN, interferon; IL, interleukin; IP, IFN-γ-inducible protein; IRR, incidence rate ratio; sCD14, soluble CD14; TNF, tumor necrosis factor.

^a Model 1 was adjusted for age, sex, country, random treatment assignment, baseline BMI, time-updated CD4⁺ T-cell count at ART24, baseline log₁₀ HIV RNA level, and baseline TB.

^b Model 2 was adjusted for age, sex, country, random treatment assignment, baseline BMI, time-updated CD4⁺ T-cell count at ART24, baseline log₁₀ HIV RNA level, baseline TB, and viral suppression at ART24 (HIV RNA <400 cp/mL).